Ovid Therapeutics (OVID) Change in Cash (2016 - 2026)

Ovid Therapeutics' Change in Cash history runs 11 years deep, the most recent figure standing at $80.9 million for Q1 2026.

• Quarterly Change in Cash rose 1666.52% year-over-year to $80.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $72.9 million (up 856.83% YoY) and the FY2025 annual result came in at -$13.1 million, down 1676.76% from the prior year.
• Change in Cash was $80.9 million for Q1 2026 at Ovid Therapeutics, up from -$7.5 million in the prior quarter.
• Across five years, Change in Cash topped out at $80.9 million in Q1 2026 and bottomed at -$93.9 million in Q2 2022.
• A 5-year average of -$5.5 million and a median of -$7.5 million in 2025 frame the typical range for Change in Cash.
• Annual changes were most pronounced in 2022 — Change in Cash plunged 349.4% — and 2026, when it jumped 1666.52%.
• Ovid Therapeutics' Change in Cash stood at -$13.4 million in 2022, then plunged by 127.01% to -$30.4 million in 2023, then jumped by 137.13% to $11.3 million in 2024, then sank by 166.09% to -$7.5 million in 2025, then surged by 1184.89% to $80.9 million in 2026.
• Business Quant data shows OVID's Change in Cash at $80.9 million in Q1 2026, -$7.5 million in Q4 2025, and -$7.8 million in Q3 2025.